UiPath Inc. (NYSE:PATH) Stock Holdings Boosted by Princeton Capital Management LLC

Princeton Capital Management LLC lifted its position in UiPath Inc. (NYSE:PATH) by 22.2% during the third quarter, Holdings Channel reports. The institutional investor owned 27,855 shares of the healthcare company’s stock after buying an additional 5,064 shares during the quarter. Princeton Capital Management LLC’s holdings in UiPath were worth $357,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of UiPath by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock worth $911,741,000 after purchasing an additional 2,133,078 shares during the last quarter. Pacer Advisors Inc. acquired a new position in UiPath in the second quarter worth approximately $69,180,000. Dimensional Fund Advisors LP grew its position in UiPath by 37.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,783,571 shares of the healthcare company’s stock worth $35,296,000 after buying an additional 754,519 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of UiPath by 20.8% in the second quarter. Bank of New York Mellon Corp now owns 2,552,921 shares of the healthcare company’s stock valued at $32,371,000 after buying an additional 439,344 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of UiPath by 120.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,633,393 shares of the healthcare company’s stock valued at $20,385,000 after acquiring an additional 892,845 shares during the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 47,671 shares of the company’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $12.07, for a total transaction of $575,388.97. Following the completion of the sale, the chief financial officer now owns 849,917 shares in the company, valued at approximately $10,258,498.19. This represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 22.37% of the stock is currently owned by company insiders.

UiPath Stock Performance

Shares of NYSE PATH opened at $12.52 on Tuesday. UiPath Inc. has a one year low of $10.37 and a one year high of $27.87. The business’s 50-day moving average price is $12.61 and its two-hundred day moving average price is $13.29.

UiPath (NYSE:PATH) last announced its quarterly earnings results on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. The business had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.09) EPS. On average, sell-side analysts predict that UiPath Inc. will post -0.23 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PATH shares. DA Davidson boosted their target price on UiPath from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Friday, September 6th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a report on Wednesday, October 23rd. JPMorgan Chase & Co. reduced their price objective on shares of UiPath from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Wednesday, October 23rd. TD Cowen dropped their target price on shares of UiPath from $17.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. Finally, Bank of America boosted their price target on shares of UiPath from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $17.47.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.